The International Waldenstrom Macroglobulinemia Foundation (IWMF) is pleased to partner with Blood Cancer United (formerly Leukemia & Lymphoma Society) to announce the launch of our 2026 Research Request for Proposals (RFP).

IWMF is the world’s leading patient-centered organization dedicated exclusively to Waldenstrom macroglobulinemia (WM) and is currently funding 32 premier academic research labs worldwide.

For 2026, IWMF is seeking proposals for research and clinical studies that will deliver therapeutic benefits for WM patients within the next 3–5 years. Grant amounts range from $250K–$1M over 2–4 years, with a separate award to support young investigators.

Working in partnership with our world-class Scientific Advisory Committee, IWMF has developed an updated 2026 Strategic Research Agenda to advance innovative discoveries, support novel clinical trials, and foster collaborations that will continue to revolutionize treatments for WM. Complete responses in WM remain very rare, and even with the best novel combination therapies to date, recurrent disease relapses are expected. IWMF is committed to identifying and supporting new insights, approaches, and therapeutics that ultimately will achieve a WM cure.

IWMF’s goal is to support translational research initiatives that elucidate the molecular basis and pathogenesis of WM; and to facilitate innovative clinical-enabling studies poised to significantly improve clinical outcomes.

Please click here to learn more about our Request for Proposals for 2026.